Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Aspire Biopharma Holdings Inc WT (ASBPW)

Aspire Biopharma Holdings Inc WT (ASBPW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 6 K
  • Annual Income, $ -12,540 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 05/13/26
  • Annual Dividend & Yield (Fwd) N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0134 +26.12%
on 03/31/26
0.0243 -30.45%
on 03/25/26
-0.0073 (-30.17%)
since 03/02/26
3-Month
0.0134 +26.12%
on 03/31/26
0.0359 -52.92%
on 01/30/26
-0.0017 (-9.14%)
since 01/02/26
52-Week
0.0100 +69.00%
on 09/09/25
0.0899 -81.20%
on 07/22/25
-0.0508 (-75.04%)
since 03/27/25

Most Recent Stories

More News
Aspire Biopharma's Subsidiary Announces Agreement with TruLife Distribution to Drive National Retail Expansion

Agreement Set to Expand BUZZ BOMB™ Distribution Across Natural, Specialty, and Mass Merchandiser Channels

ASBPW : 0.0169 (+1.81%)
ASBP : 1.0200 (+0.99%)
Aspire Biopharma's Subsidiary, Buzz Bomb Caffeine Company, Appoints John Choe as Western Sales Director

ESTERO, FL / ACCESS Newswire / March 17, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire"), wholly owned subsidiary, Buzz Bomb Caffeine Company, has appointed 25-year industry veteran John...

ASBPW : 0.0169 (+1.81%)
ASBP : 1.0200 (+0.99%)
Aspire Biopharma's Subsidiary to Feature BUZZ BOMB(TM) at The Health & Fitness Show 2026

ESTERO, FL / ACCESS Newswire / March 12, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire"), wholly owned subsidiary, Buzz Bomb Caffeine Company, announces its participation at The Health...

ASBPW : 0.0169 (+1.81%)
ASBP : 1.0200 (+0.99%)
Aspire Biopharma's BUZZ BOMB(TM) Disrupts Energy Category with New Convenience Store Pack

Convenient Size at the Convenience Store

ASBPW : 0.0169 (+1.81%)
ASBP : 1.0200 (+0.99%)
Aspire Biopharma Partners with Microsize to Develop Rapid-delivery Sublingual Powder Formulation of Alprazolam for Faster Anxiety Relief

Collaboration aims to create the first-ever sublingual alprazolam powder, addressing the need for faster-acting anxiety medication.

ASBPW : 0.0169 (+1.81%)
ASBP : 1.0200 (+0.99%)
Aspire Biopharma's Buzz Bomb(TM) Caffeine Company Achieves Record Social Media Growth and Sales Surge Following World-Record Marathon Sponsorship

BUZZ BOMB™ captures over 400,000 views and a spike in online revenue driven by strategic brand expansion and Ashley Paulson's historic record at the Jackpot Ultra Running Festival.

ASBPW : 0.0169 (+1.81%)
ASBP : 1.0200 (+0.99%)
Aspire Biopharma Regains Full Compliance with Nasdaq Listing Requirements

Company achieves minimum stockholders' equity rule; Nasdaq confirms matter is closed

ASBPW : 0.0169 (+1.81%)
ASBP : 1.0200 (+0.99%)
Aspire Biopharma's Buzz Bomb Caffeine Company Names ChicExecs as Public Relations Agency of Record

ESTERO, FL / ACCESS Newswire / February 19, 2026 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company") today announced that its wholly owned subsidiary Buzz Bomb Caffeine Company...

ASBPW : 0.0169 (+1.81%)
ASBP : 1.0200 (+0.99%)
Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Meclizine (Generic Dramamine(R))

New delivery system targets rapid-onset relief for motion sickness and vertigo, modernizing the $450M global market for the active ingredient in Dramamine®.

ASBPW : 0.0169 (+1.81%)
ASBP : 1.0200 (+0.99%)
Aspire Biopharma Announces the Appointment of New Member to Its Board of Directors

New independent director Phillip Balatsos brings commercial and capital markets expertise to drive development patent-pending drug delivery platform

ASBPW : 0.0169 (+1.81%)
ASBP : 1.0200 (+0.99%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.